After several years of working at full capacity, Sharp Regulatory Consulting now has availability to support new clients and projects. It felt like a good moment to reflect on what we have seen across the sector and why strong regulatory input continues to be such an important part of successful growth.
Over the last six years, we have supported companies across a wide range of regulatory challenges, including agency interactions, clinical trial applications, orphan drug strategy, medical device and IVD regulation, remediation programmes, and interim regulatory leadership.
What has not changed is the wider environment: regulatory complexity is still increasing. For smaller biotech and medtech companies in particular, that complexity can quickly shift from being a technical issue to a business-critical one.
- Submission timelines can slip.
- Development pathways can become unclear.
- UK, EU, US and ROW requirements continue to evolve.
- Growing teams often face internal resource gaps.
This is where experienced regulatory support can make a meaningful difference — not just by solving immediate problems, but by helping leadership teams make better decisions earlier.
At Sharp, our focus is on practical, commercially aware regulatory strategy. We work with companies to bring structure to complexity, reduce uncertainty, and help programmes move forward with greater clarity and confidence.
If your team is facing a regulatory challenge, or you simply need additional expertise at a critical stage, now may be a good time to start a conversation.